Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Xttrium Laboratories, Inc.
483
•Xttrium Laboratories, Inc.•December 6, 2024

Xttrium Laboratories, Inc. – FDA 483, Dec 6, 2024

Record Details

An FDA inspection conducted from December 3-6, 2024, at Xttrium Laboratories, Inc., an API manufacturer, revealed significant deviations from regulatory expectations at its Lake Villa, IL facility. The inspection identified six primary observations, primarily concerning the manufacturing of Chlorhexidine Gluconate (CHG). Key issues included a deficient stability testing program, with the firm failing to conduct accelerated stability studies on all validation batches and lacking forced degradation studies to ensure analytical methods were stability-indicating. An expiration date was assigned to CHG despite observed accelerated stability failures, without sufficient scientific justification or risk assessment.

Furthermore, sampling plans for process validation lacked scientific rationale, failing to ensure adequate batch representation. Cleaning validation was found inadequate, as the company failed to assess worst-case products when using shared manufacturing equipment, and cleaning procedures lacked sufficient detail. A significant deviation involving out-of-specification yields for CHG validation batches was closed without proper investigation, corrective actions, or correction of the underlying master batch record error. Lastly, observations noted issues with equipment cleanliness and construction, including discolored gaskets and unaddressed hinges, and the absence of a maintenance plan for critical components.

These findings indicate a need for comprehensive corrective actions across quality systems related to stability, process validation, cleaning validation, deviation management, and equipment control to ensure compliance with good manufacturing practices and safeguard drug substance quality.

Company
Xttrium Laboratories, Inc.
Inspection date
December 6, 2024
Product type
drugs
Office
Chicago District Office
People
  • Joohi Castelvetere
  • Vaishali J. Patel
  • Joann M (Director)
  • Tyler M. Peterson
View Company Profile

ID · 2ef6bc58-93be-4fe1-a9d1-dfbb74230750

Other documents for Xttrium Laboratories, Inc.
  • 483 - 2026-06-16June 16, 2026
  • 483 - 2025-06-18June 18, 2025
  • 483 - 2024-03-08March 8, 2024

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Xttrium Laboratories, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.